文献速递骨软组织肉瘤与黑色素瘤

黏膜黑色素瘤的自然病史与转移模式:706例前瞻性随访患者分析

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究比较了706例不同解剖部位原发黏膜黑色素瘤患者的临床病理特征,包括分期分布、转移模式、CKIT/BRAF突变状态和总生存。结果显示除口腔黏膜黑色素瘤区域淋巴结和肺转移发生率较高外,不同原发部位的呈现分期、转移部位和总生存相似。作者认为涉及黏膜黑色素瘤的临床试验和全身治疗可同等应用于不同原发部位的黏膜黑色素瘤。

要点

  • 原发部位以下消化道(26.5%)、鼻腔鼻窦(23%)、妇科(22.5%)最常见。
  • 口腔黏膜黑色素瘤区域淋巴结转移(31.7% vs 19.8%,P=0.009)和肺转移(32.5% vs 18.5%,P=0.007)高于其他原发黏膜黑色素瘤。
  • CKIT突变率10%,BRAF突变率12%。

核心结论

  • 除少数例外,不同原发解剖部位的黏膜黑色素瘤在呈现分期、淋巴结和远处转移发生率、远处转移好发部位及总生存方面相似。
  • 作者认为涉及黏膜黑色素瘤的临床试验和全身治疗可同等应用于不同原发部位的黏膜黑色素瘤。

研究设计与样本

  • 比较706例黏膜黑色素瘤患者不同解剖部位的分期分布、转移模式、CKIT/BRAF突变状态和总生存的临床病理数据分析。

主要发现

  • 原发部位为下消化道(26.5%)、鼻腔和鼻旁窦(23%)、妇科部位(22.5%)、口腔(15%)、泌尿部位(5%)、上消化道(5%)和其他部位(3.0%)。
  • 初诊时I期14.5%、II期41%、III期21.5%、IV期23.0%。
  • 主要转移部位为区域淋巴结(21.5%)、肺(21%)、肝(18.5%)和远处淋巴结(9%)。
  • 口腔黏膜黑色素瘤区域淋巴结转移发生率高于其他原发黏膜黑色素瘤(31.7% vs 19.8%,P=0.009),肺转移发生率也高于其他原发黏膜黑色素瘤(32.5% vs 18.5%,P=0.007)。
  • CKIT突变发生率10%,BRAF突变发生率12%。

关键数值与推荐

  • 口腔黏膜黑色素瘤区域淋巴结转移31.7% vs 其他原发黏膜黑色素瘤19.8%(P=0.009)。
  • 口腔黏膜黑色素瘤肺转移32.5% vs 其他原发黏膜黑色素瘤18.5%(P=0.007)。
  • CKIT突变10%,BRAF突变12%。
  • 鼻咽口腔、胃肠、妇科、泌尿来源的1年生存率分别为88%、83%、86%,2年生存率分别为66%、57%、61%,5年生存率分别为27%、16%、20%。

临床怎么用

  • 作者认为涉及黏膜黑色素瘤的临床试验和全身治疗可同等应用于不同原发部位的黏膜黑色素瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We examined whether mucosal melanomas are different in their clinical course and patterns of metastases when arising from different anatomic sites. Our hypothesis was that metastatic behavior would differ from primary mucosal melanomas at different anatomical sites. PATIENTS AND METHODS: Clinical and pathological data from 706 patients were compared for their stage distribution, patterns of metastases, CKIT/BRAF mutation status, and overall survival for different anatomical sites. RESULTS: The anatomic sites of the primary mucosal melanomas were from the lower GI tract (26.5%), nasal cavity and paranasal sinuses (23%), gynecological sites (22.5%), oral cavity (15%), urological sites (5%), upper GI tract (5%), and other sites (3.0%). At initial diagnosis, 14.5% were stage I disease, 41% Stage II, 21.5% Stage III, and 23.0% stage IV. Predominant metastatic sites were regional lymph nodes (21.5%), lung (21%), liver (18.5%), and distant nodes (9%). Oral cavity mucosal melanoma had a higher incidence of regional nodal metastases (31.7% versus 19.8%, P = 0.009), and a higher incidence of lung metastases (32.5% versus 18.5%, P = 0.007) compared to other primary mucosal melanomas. There was a 10% incidence of CKIT mutation and 12% BRAF mutation. Mucosal melanomas from nasal pharyngeal and oral, gastrointestinal, gynecological, and urological had a similar survival with a 1-year survival rate (88%, 83%, 86%), 2-year survival rate (66%, 57%, 61%), 5-year survival rate (27%, 16%, 20%), respectively. CONCLUSIONS: The largest sample size allows, for the first time, a comparison of primary melanoma stage and patterns of metastases across anatomical sites. With few exceptions, the presenting stages, incidence of nodal and distant metastases, the site of predilection of distant metastases, or overall survival were similar despite different primary anatomic sites. These findings suggest that clinical trials involving mucosal melanomas and the administration of systemic therapy can be applied equally to mucosal melanomas regardless of their primary anatomic site.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lian B, Cui CL, Zhou L, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol. 2017. PMID: 28039178. doi:10.1093/annonc/mdw694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。